Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2012 /
The immuno side of melanoma

7th - 10th Jul 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 16.07.12
Views: 3280

Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Dr Antoni Ribas talks to ecancer at EACR 22 in Barcelona about advancements in immunotherapy in melanoma patients.


Recently two unconventional methods of therapy, dabrafenib and belimumab, have shown positive results in patients where they previously have not. 


Dr Ribas focuses on understanding the immunotherapy side of melanoma and the different approaches to use the immune system in fighting cancer.


The next step for immunotherapy is seen in recent studies of PD1 antibodies, which release natural brakes in the immune system that stop forced activation. The cancer cells in turn exploits these brakes making the therapy counter productive.


Also discussed is ipilimumab and its efficacy compared to other drugs that battle BRAF.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation